Novo Nordisk's 2024 earnings exceeded estimates ... A highlight was the approval of Alhemo for treating hemophilia A and B in several major markets, including the United States and the European ...

Novo Nordisk's anti-TFPI antibody concizumab ... However, the two drugs are going after different indications. Alhemo is indicated for use in haemophilia A and B patients with inhibitors ...

Novo Nordisk got the go-ahead for its once-daily prophylactic haemophilia therapy Alhemo (concizumab ... It's the second drug in the TFPI class to be approved by the FDA after Pfizer's once ...

The latest semaglutide (Ozempic; Novo Nordisk ... drug, but patients with schizophrenia gained the first new treatment with a new mechanism of action in decades. The approval of concizumab-mtci ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock face investor scrutiny as RFK Jr. takes the leadership of HHS. Read more ...

Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

The Gates Foundation, Novo Nordisk Foundation and Wellcome have announced the launch of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a $50 million investment that will focus on ...

By contrast, Novo Nordisk is both the developer and seller of Wegovy, while Viking Therapeutics's VK2735 has posted impressive results in testing and is now in the later stages of development. Wegovy ...

During the relevant period, Novo Nordisk was conducting its highly anticipated Phase 3 study, REDEFINE-1, for CagriSema, an investigational drug developed for the treatment of obesity and type 2 ...